Subtype
Esophageal Adenocarcinoma
CI-CAN-00005190Explore in graph →
70 active trials2 approved drugs2 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005190Explore in graph →
Clinical trials
181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (27)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05177133 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)(AuspiCiOus) | recruiting | Phase 2 | 25 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04554771 | Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy(BASALT) | active not recruiting | Phase 2 | 41 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| 1 |
| Jul 29, 2024 |
| clinicaltrials |
| NCT06381583 | A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma(EMERALD) | completed | — | 658 | City of Hope Medical CenterOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT04159974 | RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus(RICE) | unknown | Phase 2 | 56 | University of CologneOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT02509286 | Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus(ESOPEC) | unknown | Phase 3 | 438 | University Hospital Schleswig-HolsteinOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT03060642 | The Microenvironment in Barrett's Esophagus(BETRNet2) | completed | — | 155 | Columbia UniversityOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
| NCT05069766 | Preoperative Marking of the Oral Resection Margin in Esophageal Cancer With a Surgical Fiducial Marker - First Experiences | completed | N/A | 10 | Rigshospitalet, DenmarkOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05591053 | Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans | unknown | N/A | 70 | Activ SurgicalINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT02830594 | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 14 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT02037048 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | unknown | Phase 2 | 63 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT03783936 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | completed | Phase 2 | 18 | Ashwin SomasundaramOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT01307956 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 2 | 11 | University of NebraskaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02971956 | Pembrolizumab in Refractory Advanced Esophageal Cancer | completed | Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05954117 | Chemotherapy in the Context of Esophageal and Gastroesophageal Junction Cancer Cachexia(CHIFMEOE) | not yet recruiting | N/A | 60 | University Hospital, Clermont-FerrandOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT02530437 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT03427346 | Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection(BEEPER) | unknown | N/A | 407 | Universitätsklinikum Hamburg-EppendorfOTHER | 2 | Jun 28, 2023 | clinicaltrials |
| NCT05247346 | Early Detection of Cancer Onset Based on Sensing Field Cancerization at the Organ Level in the Alimentary Tract Using an Integrated Stimulated Raman/Scattering Modality for Endoscopic Real-time in Vivo Measurements(SENSITIVE) | unknown | N/A | 60 | University Medical Center GroningenOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT05690958 | Public's Intended Uptake and Views on Organization of Esophageal Cancer Screening(ACCEPT-survey) | unknown | — | 2,088 | Radboud University Medical CenterOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT00574327 | Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry | recruiting | — | 3,000 | Midwest Biomedical ResearchOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT03240679 | Endoscopic Mucosal Resection and Cellular Matrix | terminated | N/A | 3 | Mayo ClinicOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT04293458 | Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE(ESOGUARDBE1) | completed | N/A | 145 | Lucid Diagnostics, Inc.INDUSTRY | 2 | Jan 25, 2023 | clinicaltrials |
| NCT00586872 | Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus | completed | — | 1,000 | Mayo ClinicOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT04642690 | Nitrates and IL-8 in Barrett's Esophagus | terminated | — | 9 | Mayo ClinicOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05642338 | A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampling (WATS) for Surveillance of Barrett's Esophagus, the WATS-EURO2 Study(WATSEURO2) | recruiting | — | 416 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05628441 | Real-time Computer Aided Detection of Barrett's Neoplasia | completed | — | 30 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT02513784 | Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome(Mouthwash) | completed | N/A | 20 | Columbia UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT01212822 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | completed | Phase 2 | 20 | Fox Chase Cancer CenterOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT05188313 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer(TRAP-2) | recruiting | Phase 3 | 376 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT00573131 | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer | terminated | Phase 2 | 137 | Boston Scientific CorporationINDUSTRY | 4 | Jun 22, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT04306458 | RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).(ROBOT-2) | recruiting | N/A | 218 | University Medical Center MainzOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT03592407 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03008980 | WATS3D for the Detection of Esophageal Dysplasia | completed | — | 160 | CDx DiagnosticsINDUSTRY | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04018872 | Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer | recruiting | Phase 2 | 78 | Dallas VA Medical CenterFED | 1 | Nov 4, 2021 | clinicaltrials |
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | withdrawn | N/A | 0 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 27, 2021 | clinicaltrials |
| NCT00591123 | Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia | completed | Phase 2 | 38 | Translational Oncology Research InternationalOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT00487695 | Confocal Endomicroscopy for Barrett's Esophagus(CEBE) | completed | Phase 3 | 46 | Johns Hopkins UniversityOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04669951 | Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer | completed | N/A | 100 | Michael Patrick AchiamOTHER | 1 | Jun 3, 2021 | clinicaltrials |
| NCT00003487 | Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus | terminated | Phase 2 | 8 | Burzynski Research InstituteOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT02128243 | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer(MATEO) | completed | Phase 2 | 242 | AIO-Studien-gGmbHOTHER | 1 | Mar 26, 2021 | clinicaltrials |
| NCT04818476 | Outcomes of Endoscopically Resected High-risk Mucosal and Low- and High-risk Submucosal Adenocarcinoma Arising in Barrett's Esophagus | unknown | — | 1,000 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 7 | Mar 26, 2021 | clinicaltrials |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 17, 2021 | clinicaltrials |
| NCT02890979 | Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease | completed | N/A | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT03474341 | Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer(PRIDE) | unknown | — | 200 | UMC UtrechtOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT04194463 | Maintaining Fitness During Neo-adjuvant Chemotherapy for Oesophago-gastric Cancer: a Feasibility Study(ChemoFit) | unknown | N/A | 40 | Newcastle-upon-Tyne Hospitals NHS TrustOTHER | 1 | Mar 12, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Aug 2, 2024source: clinicaltrials